237 related articles for article (PubMed ID: 2769847)
21. Local bacillus Calmette-Guerin therapy for superficial bladder cancer: clinical, histological and ultrastructural patterns.
Rigatti P; Colombo R; Montorsi F; Centemero A; Guazzoni G; Di Girolamo V; Galli L; Trabucchi E
Scand J Urol Nephrol; 1990; 24(3):191-8. PubMed ID: 2237295
[TBL] [Abstract][Full Text] [Related]
22. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J
J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902
[TBL] [Abstract][Full Text] [Related]
23. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
Soloway MS; Perry A
J Urol; 1987 May; 137(5):871-3. PubMed ID: 3106653
[TBL] [Abstract][Full Text] [Related]
24. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.
Lamm DL; Thor DE; Harris SC; Reyna JA; Stogdill VD; Radwin HM
J Urol; 1980 Jul; 124(1):38-40. PubMed ID: 6997513
[TBL] [Abstract][Full Text] [Related]
25. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
[TBL] [Abstract][Full Text] [Related]
26. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study.
Mori K; Lamm DL; Crawford ED
Urol Int; 1986; 41(4):254-9. PubMed ID: 3538593
[TBL] [Abstract][Full Text] [Related]
27. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
[TBL] [Abstract][Full Text] [Related]
28. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
Herr HW; Badalament RA; Amato DA; Laudone VP; Fair WR; Whitmore WF
J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
[TBL] [Abstract][Full Text] [Related]
29. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
30. Monitoring intravesical bacillus Calmette-Guerin treatment of superficial bladder carcinoma by postoperative urinary cytology.
Badalament RA; Gay H; Cibas ES; Herr HW; Whitmore WF; Fair WR; Melamed MR
J Urol; 1987 Oct; 138(4):763-5. PubMed ID: 3656528
[TBL] [Abstract][Full Text] [Related]
31. The preparation, handling and use of intravesical bacillus Calmette-Guerin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer.
Brosman SA; Lamm DL
J Urol; 1990 Aug; 144(2 Pt 1):313-5. PubMed ID: 2374197
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic problems of urine cytology on initial follow-up after intravesical immunotherapy with Calmette-Guérin bacillus for superficial bladder cancer.
Mack D; Frick J
Urol Int; 1994; 52(4):204-7. PubMed ID: 8030167
[TBL] [Abstract][Full Text] [Related]
33. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
Rintala E; Jauhiainen K; Alfthan O; Hansson E; Juusela H; Kanerva K; Korhonen H; Permi J; Sotarauta M; Vaalasti T
Eur Urol; 1991; 20(1):19-25. PubMed ID: 1743226
[TBL] [Abstract][Full Text] [Related]
34. [Progression and recurrence in the prostate and upper urinary tract following intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
Wakabayashi Y; Okada Y; Mukumoto K; Hamaguchi A; Konishi T; Tomoyoshi T
Nihon Hinyokika Gakkai Zasshi; 1993 Dec; 84(12):2146-51. PubMed ID: 8309122
[TBL] [Abstract][Full Text] [Related]
35. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
Lam JS; Benson MC; O'Donnell MA; Sawczuk A; Gavazzi A; Wechsler MH; Sawczuk IS
Urol Oncol; 2003; 21(5):354-60. PubMed ID: 14670544
[TBL] [Abstract][Full Text] [Related]
36. Persistent acid-fast bacilli following intravesical bacillus Calmette-Guerin.
Linn R; Klimberg IW; Wajsman Z
J Urol; 1989 May; 141(5):1197-8. PubMed ID: 2709508
[TBL] [Abstract][Full Text] [Related]
37. The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ.
Brosman SA
J Urol; 1985 Jul; 134(1):36-9. PubMed ID: 3892049
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic maltose tetrapalmitate and bacillus Calmette-Guerin immunotherapy of recurrent superficial bladder tumors: preliminary report.
Ibrahiem EH; Ghoneim MA; Nigam V; Brailovsky C; Elhilali MM
J Urol; 1988 Sep; 140(3):498-500. PubMed ID: 3411660
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
[TBL] [Abstract][Full Text] [Related]
40. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN
J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]